Amphstar Pharmaceuticals, Inc. (AMPH)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$23.18-2.77%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Broken: Primary pillar broken — Operating income improvement through cost control: operating income not reported.
Amphstar focuses on revenue growth, aiming to improve from $170.5M to $171.2M in Q1 2026. The company has a cheap valuation with a PE of 7.41 versus peers at 25.16. Management is stable and has authorized a $50M share buyback to support the stock. Amphstar's free cash flow yield is strong at 14%.
Revenue growth is very limited, barely rising 0.7M in a year. Operating income dropped sharply from $37.3M to $13.6M in Q1 2026. Earnings have missed estimates recently, and guidance is soft. The company faces elevated risk and a 16.4% drawdown from its high.
The market prices Amphstar about 49% below our fair value near $39, reflecting cautious views. Analysts expect modest 5.3% revenue growth, but recent earnings misses and soft guidance pressure confidence.
Breaks if: EPS falls below $2.0 in FY 2026
Breaks if: operating income falls below $13M
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a cyclical investment with a focus on the healthcare sector. The current thesis state is intact, supported by strong recent financial performance despite some challenges in operating income.
The market currently prices AMPH as cheap compared to its peers, with a notable expectations gap. This suggests that investors may not fully anticipate the potential volatility in earnings or the impact of economic conditions.
Management is on track with revenue growth, having shown consistent increases in recent quarters. However, operating income has faced pressure, which could impact overall performance if not addressed.
The thesis hinges on several factors, including management's ability to maintain revenue growth, the performance of key sector peers, and broader economic indicators such as the jobs report. Any cuts to guidance or worsening economic conditions could negatively impact sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on expanding gross margins and controlling operating expenses to enhance operating income.
Stated as a priority in 4 of last 4 quarters. Operating income declined slightly from $42.2M in 2025-Q4 to $39.7M in 2026-Q2, despite gross margin expansion from 49.6% to 50.8%. Increased manufacturing and operating expenses partly offset margin gains. The trajectory shows limited progress with margin improvement but operating income pressure.
“CEO: 'We successfully achieved expansion of gross margins...'”
“Management: 'Increased manufacturing expenses due to facility expansion impacted cost of revenues.'”
“CEO: 'Cost control efforts partially offset pricing declines.'”
“Management: 'Operating income remains a focus area with efforts to manage expenses.'”
Breaks if: quarterly revenue falls below $171M
Continue advancing product launches, marketing efforts, and pipeline development to drive overall revenue growth.
Stated as a priority in 4 of last 4 quarters. Revenue grew from $170.5M in 2025-Q1 to $183.9M in 2026-Q2, with a 5% increase in the latest quarter. Management consistently emphasized product launches and pipeline advancement to drive growth. The trajectory shows delivering on revenue growth with modest increases and new product contributions.
“CEO: 'We successfully achieved overall revenue growth, expansion of gross margins, meaningful launches of new products...'”
“CEO: 'We continued to strengthen our commercial foundation and core business, highlighted by the approval and launch of Ipratropium Bromide HFA...support sustainable long-term growth.'”
“CEO: 'BAQSIMI maintained momentum as a top revenue driver with sustained double-digit growth...we remain committed to advancing these programs...support the next phase of our growth.'”
“CEO: 'We continue to focus on expanding our product portfolio and pipeline to drive revenue growth.'”
Breaks if: PE rises above 15 without earnings growth
Over the next 1 to 3 years, AMPH's performance will depend on its ability to navigate risks while capitalizing on sector momentum. Not investment advice.